Ercros SA (ES:ECR)
BME:ECR
Want to see ES:ECR full AI Analyst Report?
Top Page
Ercros SA
(BME:ECR)
Select Model
Select Model
Rating:42Neutral
Price Target:
€3.50
▲(2.04% Upside)
Action:Reiterated
Date:03/03/26
The score is held down primarily by deteriorating financial performance (recent losses and falling revenue, plus weakening balance sheet trends). Technical indicators also point to a weak downtrend with negative momentum. Valuation provides limited support because earnings are negative and there is no dividend yield data.
Positive Factors
Diversified essential products & end markets
Ercros supplies core chemical inputs (chlor-alkali, caustic soda, chlorine and derivatives) into many industrial value chains. That product mix exposes the company to structurally recurring demand across detergents, water treatment, paper and pharmaceuticals, supporting durable baseline revenues.
Negative Factors
Sharply deteriorated profitability
Earnings have swung materially negative, reflecting margin compression and operating losses. Persistent weak profitability undermines retained earnings and the firm's ability to self-fund investments, increases reliance on external financing, and raises the bar for a durable recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified essential products & end markets
Ercros supplies core chemical inputs (chlor-alkali, caustic soda, chlorine and derivatives) into many industrial value chains. That product mix exposes the company to structurally recurring demand across detergents, water treatment, paper and pharmaceuticals, supporting durable baseline revenues.
Read all positive factors
Ercros SA (ECR) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€316.83M
Dividend Yield2.27%
Average Volume (3M)68.83K
Price to Earnings (P/E)―
Beta (1Y)0.10
Revenue Growth-6.08%
EPS Growth-359.61%
CountryES
Employees1,318
SectorGeneral
Sector StrengthN/A
IndustryChemicals
Share Statistics
EPS (TTM)-0.59
Shares Outstanding91,436,195
10 Day Avg. Volume92,838
30 Day Avg. Volume68,826
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)0.50
P/FCF Ratio15.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€662.80M
Ercros SA Business Overview & Revenue Model
Company Description
Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces am...
How the Company Makes Money
Ercros makes money primarily by manufacturing chemical products and selling them to industrial and commercial customers under supply contracts and spot/merchant sales, with revenue recognized from product deliveries. Its core revenue streams are t...
Ercros SA Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
46
Neutral
Cash Flow
54
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 626.82M | 667.41M | 725.29M | 998.53M | 772.32M |
| Gross Profit | 58.99M | 200.63M | 230.62M | 305.94M | 246.80M |
| EBITDA | 6.25M | 25.91M | 43.27M | 121.71M | 90.85M |
| Net Income | -53.59M | -11.66M | 27.59M | 62.99M | 43.30M |
Balance Sheet | |||||
| Total Assets | 694.30M | 699.19M | 683.32M | 746.55M | 709.96M |
| Cash, Cash Equivalents and Short-Term Investments | 96.03M | 31.49M | 39.15M | 55.48M | 50.30M |
| Total Debt | 223.06M | 172.34M | 131.25M | 135.43M | 120.00M |
| Total Liabilities | 396.07M | 358.03M | 320.20M | 385.84M | 378.34M |
| Stockholders Equity | 287.25M | 341.16M | 363.12M | 360.71M | 331.61M |
Cash Flow | |||||
| Free Cash Flow | 20.04M | -4.04M | 17.30M | 35.80M | 47.42M |
| Operating Cash Flow | 49.19M | 9.51M | 51.14M | 62.99M | 60.32M |
| Investing Cash Flow | -29.15M | -26.67M | -33.84M | -52.81M | -34.24M |
| Financing Cash Flow | 40.04M | 14.33M | -35.91M | -21.45M | -14.68M |
Ercros SA Technical Analysis
Positive
3.43
Price Trends
3.42
Positive
3.39
Positive
3.17
Positive
Market Momentum
0.01
Negative
63.15
Neutral
80.36
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ECR, the sentiment is Positive. The current price of 3.43 is above the 20-day moving average (MA) of 3.41, above the 50-day MA of 3.42, and above the 200-day MA of 3.17, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 63.15 is Neutral, neither overbought nor oversold. The STOCH value of 80.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:ECR.
Ercros SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | €24.12B | 10.41 | 10.51% | 6.18% | -0.48% | 124.35% | |
60 Neutral | €3.00B | 22.68 | 20.89% | 1.50% | -3.44% | -5.45% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €5.69B | 15.09 | 7.88% | 1.37% | 0.89% | 112.68% | |
51 Neutral | €1.45B | 10.70 | 18.13% | 3.51% | 23.66% | -28.51% | |
46 Neutral | €220.51M | 50.23 | 2.03% | 1.91% | -3.23% | -60.06% | |
42 Neutral | €316.83M | -4.72 | -20.66% | 2.27% | -6.08% | -359.61% |
* General Sector Average
ES:ECR
Ercros SA
3.46
0.46
15.55%
ES:FAE
Faes Farma
4.56
0.38
9.17%
ES:GRF
Grifols
9.21
-0.32
-3.41%
ES:RJF
LABORATORIO REIG JOFRE
2.71
-0.40
-12.97%
ES:ROVI
Laboratorios Farmaceuticos Rovi
58.45
5.28
9.94%
ES:REP
Repsol
22.63
11.27
99.30%
Ercros SA Corporate Events
Ercros Calls June 30 Meeting to Approve Delisting and Board Overhaul
May 28, 2026
Ercros has called a general shareholders’ meeting for June 30, 2026 in Barcelona, with a key agenda item being the proposed delisting of its shares from the stock exchange and a related public tender offer by Bondalti Iberica at 3.505 euros ...
Ercros Reshapes Board and Committees Under New Controlling Shareholder Bondalti
Apr 8, 2026
Ercros has overhauled its board following the arrival of new controlling shareholder Bondalti Iberica, appointing Anton Valero Solanellas, João Maria Guimaraes José de Mello and André Cabral Côrte-Real de Alburquerque as direct...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.